Business Context and Reporting Period
This Form 8-K Current Report was filed by MEDICINOVA INC on January 12, 2010. The report addresses corporate governance changes, specifically the departure of a director and subsequent committee reassignments.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial performance data.
Material Changes
- Director Resignation: Mr. Hideki Nagao resigned from the Board of Directors effective January 12, 2010.
- Committee Roles: Prior to resignation, Mr. Nagao served on the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Reason for Departure: The resignation was not due to any disagreement with the company regarding operations, policies, or practices, but rather to pursue other interests.
Outlook, Risks, and Management Commentary
Management confirmed the transition of committee responsibilities to ensure continuity:
- Audit and Nominating Committees: Mr. Hiroaki Shigeta (joined Board in September 2009) replaced Mr. Nagao.
- Compensation Committee: Dr. Jeff Himawan (Chairman of the Board) replaced Mr. Nagao.
- Additional Change: Dr. Himawan also replaced Ms. Arlene Morris on the Nominating and Corporate Governance Committee. Ms. Morris remains on the Audit and Compensation Committees.
No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of Mr. Nagao's resignation (January 12, 2010).
- Verify the new composition of the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Note that the departure was voluntary and unrelated to company disputes.